New Research by Proove Biosciences Presented at the 40th Annual Regional Anesthesiology and Acute Pain Medicine Meeting

Proove Biosciences presented three research studies at the 40th Annual ASRA Acute Pain Medicine Meeting in Las Vegas, Nevada last week.

(PRWEB) July 10, 2015 -- Proove Biosciences, a commercial and research leader in Personalized Medicine, presented updated data on genetics, opioids, and depression at the 40th Annual Regional Anesthesiology and Acute Pain Medicine Meeting in Las Vegas, NV on May 14-16, 2015. The meeting took place at the Caesars Palace and attracted approximately 1000 attendees and physicians dedicated to advancing the science and practice of regional anesthesiology and pain medicine.

Proove Biosciences presented the Genetics and Drug Response: Study on the Role of Genetics in Individual Variations in Response to Methadone Use, a study designed to determine the role of genetics in observed individual variations in response to methadone use. The study involved 31 subjects currently taking methadone for chronic non-cancer pain, the results of which found the genetic variation of C/T and T/T to be more associated with good response to methadone while C/C was found to be associated with poor response.

Also presented was the Study to Comprehensively Calculate Risk of Aberrant Behavior to Opioids by Incorporating Genetic and Phenotypic Risk Factors in Pain Patients, the objective of which is to determine the predictability of misuse, abuse, dependence, and addiction to opioids by analyzing genetic variables and phenotypic risk factors. After analyzing the DNA of 162 pain patients (80 of which were diagnosed with opioid drug dependence, 82 of which were not and served as a control population), Proove Biosciences used a scoring algorithm called the Opioid Risk Index (a scale of 0-52) in an attempt to predict the risk of aberrant behavior. Results showed a significant association between Opioid Drug Dependence and Opioid Risk Index score; an Opioid Risk Index score of greater than or equal to 13 is a good cutoff to predict risk of aberrant behavior to opioid pain relievers.

The final presentation was on Depression and Pain Perception: Study on Pain Perception in Subjects with Reported History of Depression, Proove Biosciences study to help determine if any association exists between subjects with history of depression and chronic pain. The study took 2092 pain subjects (1030 with diagnosed depression, 1062 controls) and compared their Pain Numeric Ratings Scale scores. After finding significant difference in pain perception between subjects with a history of depression and the controls, further analysis suggests that subjects with a reported history of depression are more likely to be associated with high pain perception as compared to those with no history of depression.

“A hot topic at the ASRA conference this year was how anesthesiologists have a responsibility to decrease exposure to opioids in order to prevent addiction,” Maggie Hopkins, a Clinical Science Liaison at Proove Biosciences and presenting author of the posters, said. “With one in 15 patients given opioids acutely progressing to chronic use, Proove testing can be a powerful component to a pre-surgical workup to decrease the risk of opioid abuse and misuse by identifying patients at a higher risk of addiction and identifying the best medications to control.”

About Proove Biosciences:
Our Mission is to Change the Future of Medicine. Proove is the proof to improve healthcare decisions. We seek to realize a future when clinicians look back and wonder how they could’ve ever prescribed medications
without knowing how a patient would respond. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of personalized pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve outcomes – both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).
Contact Information
Nicole McMillan
Proove Biosciences
http://www.proovebio.com
+1 855-776-6832 Ext: 1546

Online Web 2.0 Version
You can read the online version of this press release here.